Morgan Stanley Amylyx Pharmaceuticals, Inc. Transaction History
Morgan Stanley
- $1.39 Trillion
- Q4 2024
A detailed history of Morgan Stanley transactions in Amylyx Pharmaceuticals, Inc. stock. As of the latest transaction made, Morgan Stanley holds 464,220 shares of AMLX stock, worth $2.28 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
464,220
Previous 478,265
2.94%
Holding current value
$2.28 Million
Previous $1.55 Million
12.98%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding AMLX
# of Institutions
141Shares Held
48.9MCall Options Held
281KPut Options Held
438K-
Perceptive Advisors LLC New York, NY6.77MShares$33.3 Million0.85% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA4.64MShares$22.8 Million2.86% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.69MShares$13.2 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.67MShares$13.1 Million0.0% of portfolio
-
Bank Of America Corp Charlotte, NC2.43MShares$11.9 Million0.0% of portfolio
About Amylyx Pharmaceuticals, Inc.
- Ticker AMLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,533,200
- Market Cap $288M
- Description
- Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...